Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $34.42

Posted by on Aug 25th, 2026

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $34.4167.

Several research analysts recently commented on DYN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Royal Bank Of Canada increased their price objective on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Finally, TD Cowen initiated coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating for the company.

Read Our Latest Stock Report on DYN

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 4,139,196 shares of company stock worth $99,449,852. 9.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning grew its position in Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after acquiring an additional 1,440 shares during the period. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics during the first quarter valued at $26,000. Caxton Associates LLP boosted its stake in shares of Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 0.4%

Shares of DYN opened at $25.99 on Friday. The stock’s 50-day moving average price is $23.83 and its 200 day moving average price is $19.83. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $4.85 billion, a price-to-earnings ratio of -7.80 and a beta of 1.07. Dyne Therapeutics has a 12-month low of $11.92 and a 12-month high of $27.31.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, research analysts predict that Dyne Therapeutics will post -3.47 earnings per share for the current year.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Featured Stories

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.